IP Library Granted Patent US 8,304,578
Granted Patent B2
US 8,304,578 · App. 12/810,791 · Granted Nov 6, 2012

Process for producing 1-[2-(dimethylamino)-1-(4-phenol)ethyl]cyclohexanol

Assignee: Matrix Laboratories Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,304,578
App. No.
12/810,791
Granted
Nov 6, 2012
Kind
B2
Abstract

The present invention relates to an improved, process for large scale production of 1-[2-(dimethylamino)-1-(4-phenol)ethyl]cyclohexanol (O-desmethylvenlafaxine) or its pharmaceutically acceptable salts with increased yield and minimal impurities.

Claims (28)

1. A process for preparing 1-[2-(dimethylamino)-1-(4-phenol)ethyl]cyclohexanol (O-desmethylvenlafaxine) or its pharmaceutically acceptable salt thereof,

wherein the process comprises:

(a) reducing 1-[cyano(substituted benzyloxyphenyl) methyl] cyclohexanol of formula (II) with reducing agent sodiumborohydride-iodine or sodiumborohydride-trifluoroacetic acid in presence of a solvent to obtain 1-[2-amino-1-(substituted benzyloxyphenyl)ethyl]cyclohexanol of formula (III);

wherein R is selected from phenyl, nitrophenyl, hydroxyphenyl or halophenyl;

(b) alkylating the 1-[2-amino-1-(substituted benzyloxyphenyl)ethyl]cyclohexanol of formula (III) to obtain compound of formula IV; and

(c) deprotecting the compound of formula (IV) to obtain O-desmethylvenlafaxine.

2. The process according to claim 1 , wherein the reducing agent comprises sodium borohydride-iodine.

3. The process according to claim 1 , wherein the solvent is selected from ether, aliphatic hydrocarbon or alcohol or mixture thereof.

4. The process according to claim 2 , wherein the solvent is selected from tetrahydrofuran, hexane, cyclohexane, heptane, pentane, methanol, ethanol or isopropyl alcohol.

5. The process according to claim 1 , wherein the alkylation is performed employing an alkylating agent selected from formaldehyde and formic acid, methyl iodide or dimethyl sulphate.

6. The process according to claim 1 , wherein the deprotection is carried out in presence of metal catalyst under hydrogen pressure.

7. The process according to claim 6 , wherein the metal catalyst is selected from Raney nickel or palladium on carbon.

8. The process for preparing O-desmethylvenlafaxine according to claim 1 , wherein the 1-[cyano(substituted benzyloxyphenyl) methyl) cyclohexanol of formula (II) is prepared by reacting substituted benzyloxyphenyl acetonitrile of formula (I),

wherein R is selected from phenyl, nitrophenyl, hydroxyphenyl, or halophenyl, with cyclohexanone in presence of a base and a phase transfer catalyst (PTC) in a solvent.

9. The process according to claim 8 , wherein the base is selected from alkali metal hydroxide, alkali metal alkoxide, alkali earth metal hydroxide, alkali earth metal oxide, lithium hexmethylenedisilane or mixture thereof.

10. The process according to claim 9 , wherein the alkali metal hydroxide is selected from sodium hydroxide and potassium hydroxide or mixture thereof.

11. The process according to claim 9 , wherein the alkali metal alkoxide is selected from sodium methoxide, sodium tertiarybutoxide, potassium methoxide, and potassium tertiarybutoxide or mixture thereof.

12. The process according to claim 9 , wherein the alkali earth metal hydroxide is selected from magnesium hydroxide and calcium hydroxide or mixture thereof.

13. The process according to claim 9 , wherein the alkali earth metal oxide is selected from calcium oxide, magnesium oxide or mixture thereof.

14. The process according to claim 8 , wherein the phase transfer catalyst is selected from tetrabutylammonium hydrogensulphate, tetrabutylammonium bromide, tetrabutylammonium chloride, tetrabutyl ammonium iodide, benzyltriethyl ammonium chloride, polyethylene glycol-400, or N-methyl-N,N-dioctyloctan-1-ammonium chloride.

15. The process according to claim 8 , wherein the solvent used is selected from alcohol, aliphatic hydrocarbons, aromatic hydrocarbons or ethers.

16. The process according to claim 15 , wherein the solvent is selected from methanol, ethanol, isopropyl alcohol, hexane, heptane, cyclohexane, toluene, xylene tetrahydrofuran, 1,4-dioxane, diethyl ether, diisopropyl ether or isopropyl ether.

17. The process according to claim 1 , wherein the process comprises optionally treating the 1-[2-amino-1-(substituted benzyloxyphenyl)ethyl] of formula (III) with an acid to obtain an acid addition salt having formula (IIIa),

wherein R is selected from phenyl, nitrophenyl, hydroxyphenyl or halophenyl.

18. The process according to claim 17 , wherein the acid used is selected from hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid or p-toluene sulphonic acid.

19. The process according to claim 1 , wherein the process further comprises treating the O-desmethylvenlafaxine with an acid in a solvent to give pharmaceutically acceptable acid addition salt of O-desmethylvenlafaxine.

20. The process according to claim 19 , wherein the acid comprises succinic acid.

21. The process according to claim 19 , wherein the solvent is selected from methanol, ethanol, n-propanol, isopropanol or mixture thereof.

Assignments (4)
CHANGE OF NAME Recorded Jan 12, 2026
From: TIANISH LABORATORIES PRIVATE LIMITED
To: MATRIX PHARMACORP PRIVATE LIMITED
Reel/Frame 074322/0525 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: MYLAN LABORATORIES LIMITED
To: TIANISH LABORATORIES PRIVATE LIMITED
Reel/Frame 068861/0150 →
CHANGE OF NAME Recorded Jul 29, 2013
From: MATRIX LABORATORIES LIMITED
To: MYLAN LABORATORIES LIMITED
Reel/Frame 030898/0514 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2012
From: TYAGI, OM DUTT; LAHIRI, SASWAT; KOILKONDA, PURANDHAR; TUMMANAPALLY, JAGAN MOHANA CHARY; VADLAMUDI, MOHAN VAMSI KRISHNA; INUPAKUTIKA, VENKATA BALA KISHORE SARMA; ACHANTA, SURYA NAGESWARA RAO
To: MATRIX LABORATORIES LIMITED
Reel/Frame 029082/0669 →
Priority Claims (1)
IN 3108/CHE/2007 · Dec 26, 2007 · national
Continuity (1)
Related Publication 20100286447A1 · Nov 11, 2010